Park Medi World Shares Climb Near Record High After Strong Q1 FY27 Earnings; Announces Major Expansion in Uttarakhand
Shares of Park Medi World Ltd extended their winning streak for the fourth consecutive trading session on Monday, rising close to their all-time high after the healthcare company reported a robust set of earnings for the quarter ended June 2026 (Q1 FY27).
The stock opened higher at ₹299 on the NSE and touched an intraday high of ₹300.60, just a few rupees below its record high of ₹305. The rally was supported by strong quarterly financial performance and the company’s continued expansion plans.
For the April-June quarter, Park Medi World reported revenue from operations of ₹475.70 crore, marking a 19 percent year-on-year (YoY) increase.
Operating performance also remained healthy, with EBITDA rising 20 percent YoY to around ₹126 crore, while the EBITDA margin improved to 26.5 percent, expanding by 20 basis points compared with the corresponding period last year.
The company’s net profit surged 35 percent YoY to ₹88.60 crore, with the net profit margin expanding to 18.6 percent, reflecting improved operational efficiencies and healthy demand across its hospital network.
Park Medi World continues to strengthen its presence across North India through capacity additions. The company expects to add 1,490 beds during calendar year 2026, representing nearly 46 percent growth over its existing capacity of 3,250 beds at the end of 2025. According to the company, this will be its largest annual bed addition to date.
Further boosting investor sentiment, the company recently announced the launch of The Medicity Hospital, Rudrapur, a 330-bed multi-speciality hospital that will be the largest healthcare facility in Uttarakhand’s Kumaon region. The expansion marks Park Medi World’s entry into Uttarakhand and extends its operational footprint to six states across North India.
Since its stock market debut in December 2025, Park Medi World has delivered impressive returns to investors. The stock has nearly doubled from its IPO price and has remained among the better-performing healthcare counters, supported by consistent earnings growth, disciplined expansion, and increasing investor confidence in its long-term growth strategy.
